AstraZeneca's Imfinzi gains EU approval for treating muscle-invasive bladder cancer, offering a promising neoadjuvant and adjuvant therapy based on pivotal trial results...
AstraZeneca has successfully acquired EsoBiotec, enhancing its cancer therapy capabilities with innovative in vivo cell therapies that promise faster treatment access...
AstraZeneca's Imfinzi shows promise in improving disease-free survival for high-risk non-muscle-invasive bladder cancer, as highlighted by recent POTOMAC trial results...
AstraZeneca’s Calquence, combined with bendamustine and rituximab, is now EU approved for untreated mantle cell lymphoma, offering a significant survival advantage...
AstraZeneca's Breztri has shown significant promise in treating uncontrolled asthma, meeting primary endpoints in the KALOS and LOGOS Phase III trials...
The DESTINY-Breast09 Phase III trial of Enhertu marks a breakthrough for HER2-positive metastatic breast cancer, showcasing superior efficacy over traditional therapies...
AstraZeneca and Daiichi Sankyo's Enhertu gains EU approval for treating HR-positive, HER2-low metastatic breast cancer, offering new hope for patients...
AstraZeneca's Imfinzi has received FDA approval as a groundbreaking treatment for muscle-invasive bladder cancer, significantly improving patient outcomes in clinical trials...
AstraZeneca is set to transform cancer treatment by acquiring EsoBiotec, a leader in in vivo cell therapies that promise quicker, more effective patient care...
The MATTERHORN Phase III trial reveals promising results for AstraZeneca's Imfinzi in enhancing event-free survival for patients with early-stage gastric cancer...
AstraZeneca's Imfinzi receives FDA approval for limited-stage small cell lung cancer, marking a significant breakthrough in extending patient survival...
AstraZeneca's Imfinzi gains EU approval for treating muscle-invasive bladder cancer, offering a promising neoadjuvant and adjuvant therapy based on pivotal trial results...
AstraZeneca has successfully acquired EsoBiotec, enhancing its cancer therapy capabilities with innovative in vivo cell therapies that promise faster treatment access...
AstraZeneca's Imfinzi shows promise in improving disease-free survival for high-risk non-muscle-invasive bladder cancer, as highlighted by recent POTOMAC trial results...
AstraZeneca’s Calquence, combined with bendamustine and rituximab, is now EU approved for untreated mantle cell lymphoma, offering a significant survival advantage...
AstraZeneca's Breztri has shown significant promise in treating uncontrolled asthma, meeting primary endpoints in the KALOS and LOGOS Phase III trials...
The DESTINY-Breast09 Phase III trial of Enhertu marks a breakthrough for HER2-positive metastatic breast cancer, showcasing superior efficacy over traditional therapies...
AstraZeneca and Daiichi Sankyo's Enhertu gains EU approval for treating HR-positive, HER2-low metastatic breast cancer, offering new hope for patients...
AstraZeneca's Imfinzi has received FDA approval as a groundbreaking treatment for muscle-invasive bladder cancer, significantly improving patient outcomes in clinical trials...
AstraZeneca is set to transform cancer treatment by acquiring EsoBiotec, a leader in in vivo cell therapies that promise quicker, more effective patient care...
The MATTERHORN Phase III trial reveals promising results for AstraZeneca's Imfinzi in enhancing event-free survival for patients with early-stage gastric cancer...
AstraZeneca's Imfinzi receives FDA approval for limited-stage small cell lung cancer, marking a significant breakthrough in extending patient survival...
